Navigation Links
Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
Date:10/12/2010

BEDFORD, Mass., Oct. 12 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

The study was a single-site, single-armed, single-dose study in which ten patients received the punctum plug immediately following cataract surgery and were evaluated over a 10-day period. Primary outcome measures were plug retention and moxifloxacin levels above the minimum inhibitory concentration (MIC) to stop growth in various strains of bacterial conjunctivitis.

The moxifloxacin punctum plug achieved 100% retention in all 10 patients as proven via tear fluid testing.  Pharmacokinetic data demonstrated that tear sample drug levels were maintained between 2,000 and 3,000 ng/ml over a 7 day period. These levels were well above MIC90, the concentration necessary to inhibit bacterial growth of staphylococcus aureus, staphylococcus epidermidis, and streptococcus pneumonia (</= MIC90 = 250 ng/ml).  No adverse events were reported, and there were no ocular complaints outside of normal post-cataract symptoms.

Principal Investigator for the study, Dr. Soon Phaik Chee of the Singapore National Eye Centre in Singapore, commented that "Ocular Therapeutix's moxifloxacin punctum plugs were easy to use and insert.  In addition to the fact that the plugs were retained and released favorable and sustained levels of moxifloxacin, I was impressed at the patients' level of comfort – not one of the patients complained of foreign body sensation or discomfort in relation to the plugs following surgery."

The innovative platform technology uses Ocular Therapeutix's proprietary and patented polyethylene glycol (PEG) hydrogel to encase drug-loaded polylactide-co-glycolide (PLGA) microspheres.  After insertion, the plugs gently expand upon contact with moisture providing a universal fit, and releas
'/>"/>

SOURCE Ocular Therapeutix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sylentis Completes Phase I Trial with SYL040012 to Treat Elevated Intraocular Pressure and Glaucoma
2. Tekia Enters Into Distribution Agreement With Fritz Ruck/T-MED, Germany to Market Its Accommodative Intraocular Lens to Treat Presbyopia
3. Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
4. Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
5. Ocular Therapeutix, Inc. Appoints Two New Board Members
6. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
7. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
10. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
11. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
(Date:8/3/2015)... Inc. (PK:ECIA), a medical device company owning patented surgical ... invasive surgery, today announced financial results for its fiscal ... The Company posted quarterly net revenue of $2.454 ... or $(0.02) per share. These results compare to net ... $202 thousand, or $(0.02) per share, in the year-ago ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , ST. LOUIS , Feb. 8 ... its first Stereotaxis Magnetic Navigation System in Taiwan at ... a Grand Opening event on January 26 that received ... been successfully performed using Stereotaxis at the hospital. , "All too ...
... Md. , Feb. 8 Novavax, Inc. (Nasdaq: ... to discontinue negotiations in its pursuit of the previously announced ... Novavax,s virus-like-particle (VLP)-based vaccines against influenza in the country of ... inability to agree on acceptable terms of the proposed collaboration ...
Cached Medicine Technology:Stereotaxis Installs First System in Taiwan 2Stereotaxis Installs First System in Taiwan 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... global insurance brokerage firm, announced today that Joe Williams has joined its growing ... sales, and delivering HUB's differentiated service model to his clients. Mr. Williams will ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... August 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can ... can’t afford to start a business.” Neither needs be a major obstacle. , The ... to start a business and be successful. The risks of starting a business can be ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5
... how much control a person has over their own health ... that when doctor and patient attitudes on the issue match ... Published online and in the May issue of the ... part of a growing body of evidence indicating that patient-physician ...
... have already adopted guidelines, group says , WEDNESDAY, April ... for how medical organizations should interact with private companies ... Societies (CMSS). , "Physicians and patients count on medical ... medicine," Dr. Allen Lichter, CEO of the American Society ...
... In rats, approach minimized dangerous bleeding around spinal cord ... rats is raising new hope for a treatment that might ... often follows such trauma. , Researchers found that by immediately ... gene, they could halt the dangerous bleeding that occurs at ...
... ago that the genes BRCA1 and BRCA2 confer high ... for cancer prediction and therapy, especially for familial cases. ... rechts der Isar of the Technische Universitaet Muenchen), in ... the U.S., can identify another gene that increases susceptibility ...
... Older whites with less education least likely to be screened, ... few middle-aged and older white Americans are being screened for ... finish high school or receive other common cancer screenings, a ... white men and women, aged 50 and older, who took ...
... ... Barrel Safety Syringe , ... Mission Viejo, CA (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , ... Dr. Robert W. Beart, Emeritus Professor of Surgery at Keck School of Medicine, University ...
Cached Medicine News:Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:Voluntary Ethics Code Set for Medical Organizations 2Health News:Gene-Targeted Therapy Might Help Prevent Paralysis 2Health News:Gene-Targeted Therapy Might Help Prevent Paralysis 3Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Few Over 50 Get Skin Cancer Screenings 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa cemented stem....
Porous foundation 480 series....
Porous foundation 440 series....
Medicine Products: